Drugs / 18F-Fluoropaclitaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01086696 | Mar 2010 → Aug 2014 | adrenal gland cancer, breast cancer, kidney cancer, lung cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Fluoropaclitaxel | “18F-Fluoropaclitaxel (FPAC) is a form of paclitaxel that has been modified to be slightly radioactive in order to show up on positron emission tomography (PET) scans.” NCT01086696 ↗ |
| Known as | FPAC | “18F-Fluoropaclitaxel (FPAC) is a form of paclitaxel that has been modified to be slightly radioactive in order to show up on positron emission tomography (PET) scans.” NCT01086696 ↗ |
| Modality | Diagnostic / imaging agent | “modified to be slightly radioactive in order to show up on positron emission tomography (PET) scans” NCT01086696 ↗ |